{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T12:08:14Z","timestamp":1779451694017,"version":"3.53.1"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"1182","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"DST-SERB"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The diagnostic performance of 99mTc-HYNIC-PSMA-11 whole-body SPECT\/CT versus 68Ga-PSMA PET\/CT was evaluated in prostate cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>As a part of the diagnostic workup, all the prostate cancer (PCa) patients (n\u2009=\u200910; mean age 66.4\u2009\u00b1\u20099.6\u2009years) underwent whole-body 68Ga-PSMA-11 PET\/CT followed by serial whole-body (anterior and posterior) 99mTc-HYNIC-PSMA-11 imaging The serial whole-body imaging was performed at multiple time points of 10\u2009minutes, 2\u2009hours, 4\u2009hours, 6\u2009hours, 24\u2009hours and the whole-body SPECT\/CT was acquired at 3\u2009hours. The whole-body SPECT\/CT data was analysed for lesions detection and to calculate the standardized uptake values (SUVmax) for 99mTc-HYNIC-PSMA-11 avid lesions using the Q-Metrix software. These values were compared with the corresponding SUVmax values obtained from 68Ga-PSMA-11 PET\/CT. The serial whole-body imaging data were used for estimating the radiation absorbed doses (mSv\/MBq) to various organs using the MIRD schema and the OLINDA\/EXM software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>68Ga-PSMA-11 PET\/CT identified a total of 64 metastatic lesions, while 99mTc-HYNIC-PSMA-11 SPECT\/CT detected 49\/64 metastatic lesions, presenting a sensitivity of 76.6%. Notably, the mean SUVmax values for 68Ga-PSMA-11 PET\/CT and 99mTc-HYNIC-PSMA-11 were comparable and a highly significant positive correlation (r\u2009&amp;gt;\u20090.93; P\u2009&amp;lt;\u2009.01) The average absorbed doses to the salivary glands, lungs, kidneys, urinary bladder, and liver were found to be comparable with 99mTc-MDP bone scanning.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The diagnostic performance of whole-body 99mTc-HYNIC PSMA-11 SPECT\/CT is fairly comparable to 68Ga-PSMA PET\/CT and offers a favourable dosimetry indicating its potential for PCa evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Advances in knowledge<\/jats:title>\n                    <jats:p>99mTc-PSMA-11 SPECT\/CT may be an alternative and cost-effective tool for evaluation of initial PSMA disease burden as well as for response evaluation to PSMA targeted therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjr\/tqag052","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T20:14:16Z","timestamp":1773346456000},"page":"1081-1091","source":"Crossref","is-referenced-by-count":0,"title":["99mTc-HYNIC-PSMA-11 whole-body SPECT\/CT: a clinically viable alternative to 68Ga-PSMA PET\/CT in patients with prostate cancer"],"prefix":"10.1093","volume":"99","author":[{"given":"Monika","family":"Hooda","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research (PGIMER) , Chandigarh 160012,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komalpreet","family":"Kaur","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research (PGIMER) , Chandigarh 160012,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Watts","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research (PGIMER) , Chandigarh 160012,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harmandeep","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research (PGIMER) , Chandigarh 160012,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harneet","family":"Kaur","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research (PGIMER) , Chandigarh 160012,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinisha","family":"Gunasekaran","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research (PGIMER) , Chandigarh 160012,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya P","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Urology, Postgraduate Institute of Medical Education and Research (PGIMER) , Chandigarh 160012,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravimohan","family":"Mavuduru","sequence":"additional","affiliation":[{"name":"Department of Urology, Postgraduate Institute of Medical Education and Research (PGIMER) , Chandigarh 160012,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8464-7765","authenticated-orcid":false,"given":"Baljinder","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research (PGIMER) , Chandigarh 160012,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"2026052207303453500_tqag052-B1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026052207303453500_tqag052-B2","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1002\/cncr.31384","article-title":"Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer\u2014a population-based analysis of 2 national cohorts","volume":"124","author":"Helgstrand","year":"2018","journal-title":"Cancer"},{"key":"2026052207303453500_tqag052-B3","doi-asserted-by":"publisher","first-page":"627379","DOI":"10.3389\/fonc.2020.627379","article-title":"Metastatic spread in prostate cancer patients influencing radiotherapy response","volume":"10","author":"Klusa","year":"2020","journal-title":"Front Oncol"},{"key":"2026052207303453500_tqag052-B4","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.3390\/ph15101292","article-title":"[177Lu] Lu-PSMA-617 (PluvictoTM): the first FDA-approved radiotherapeutical for treatment of prostate cancer","volume":"15","author":"Hennrich","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026052207303453500_tqag052-B5","doi-asserted-by":"crossref","first-page":"e233460","DOI":"10.1148\/radiol.233460","article-title":"Quantitative 68Ga-PSMA-11 PET and clinical outcomes in metastatic castration-resistant prostate cancer following 177Lu-PSMA-617 (VISION trial)","volume":"312","author":"Phillip","year":"2024","journal-title":"Radiology"},{"key":"2026052207303453500_tqag052-B6","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.2967\/jnumed.121.262713","article-title":"Prostate-specific membrane antigen radioligand therapy using 177Lu-PSMA I&T and 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution, and dosimetry","volume":"63","author":"Schuchardt","year":"2022","journal-title":"J Nucl Med"},{"key":"2026052207303453500_tqag052-B7","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1097\/RLU.0000000000003702","article-title":"Comparing 99mTc-PSMA to 99mTc-MDP in prostate cancer staging of the skeletal system","volume":"46","author":"Kabunda","year":"2021","journal-title":"Clin Nucl Med"},{"key":"2026052207303453500_tqag052-B8","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1055\/a-1035-9052","article-title":"Determination of whole-body tumour burden on [68Ga]PSMA-11 PET\/CT for response assessment of [177Lu]PSMA-617 radioligand therapy: a retrospective analysis of serum PSA level and imaging derived parameters before and after two cycles of therapy","volume":"58","author":"Michalski","year":"2019","journal-title":"Nuklearmedizin"},{"key":"2026052207303453500_tqag052-B9","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1097\/MNM.0000000000001361","article-title":"Comparison of the diagnostic utility of 99mTc PSMA scintigraphy versus 68Ga-PSMA-11 PET\/CT in the detection of metastatic prostate cancer and dosimetry analysis: a gamma-camera-based alternate prostate specific membrane antigen imaging modality","volume":"42","author":"Singh","year":"2021","journal-title":"Nucl Med Commun"},{"key":"2026052207303453500_tqag052-B10","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1097\/RLU.0000000000005754","article-title":"Can 99mTc-PSMA SPECT\/CT presenting mirror image of 68Ga-PSMA PET\/CT be used for response assessment to 177Lu-PSMA in metastatic castration-resistant prostate cancer?","volume":"50","author":"Hooda","year":"2025","journal-title":"Clin Nucl Med"},{"key":"2026052207303453500_tqag052-B11","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.2967\/jnumed.115.168443","article-title":"Radioligand therapy of metastatic castration resistant prostate cancer: safety and efficacy","volume":"57","author":"Baum","year":"2016","journal-title":"J Nucl Med"},{"key":"2026052207303453500_tqag052-B12","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/pros.24531","article-title":"Response to RL-225Ac in prostate cancer: effect of prior treatment with RL-177Lu: a systematic review of the literature","volume":"83","author":"Kremser","year":"2023","journal-title":"Prostate"},{"key":"2026052207303453500_tqag052-B13","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.2967\/jnumed.124.267606","article-title":"Comparison of posttherapy 4- and 24-hour [177Lu]Lu-PSMA SPECT\/CT and pretherapy PSMA PET\/CT in assessment of disease in men with metastatic castration-resistant prostate cancer","volume":"65","author":"Swiha","year":"2024","journal-title":"J Nucl Med"},{"key":"2026052207303453500_tqag052-B14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.5005\/jp-journals-10028-1050","article-title":"Can the standardized uptake values derived from diagnostic 68Ga-DOTATATE PET\/CT imaging predict the radiation dose delivered to the metastatic liver NET lesions on 177Lu-DOTATATE peptide receptor radionuclide therapy?","volume":"47","author":"Singh","year":"2013","journal-title":"J Postgrad Med Edu Res"},{"key":"2026052207303453500_tqag052-B15","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1007\/s00259-016-3609-9","article-title":"The 68Ga\/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates","volume":"44","author":"Scarpa","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026052207303453500_tqag052-B16","doi-asserted-by":"publisher","first-page":"122","DOI":"10.4103\/0972-3919.152972","article-title":"Deviation in the predefined calibration factors of the dose calibrators and the associated inaccuracy in the radio activity measurements of beta\/gamma emitters","volume":"30","author":"Sharma","year":"2015","journal-title":"Indian J Nucl Med"},{"key":"2026052207303453500_tqag052-B17","volume-title":"Fundamentals of Nuclear Dosimetry","author":"Stabin","year":"2008"},{"key":"2026052207303453500_tqag052-B18","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3389\/fmed.2017.00046","article-title":"Comparative therapeutic efficacy of 153Sm-EDTMP and 177Lu-EDTMP for bone pain palliation in patients with skeletal metastases: patients\u2019 pain score analysis and personalized dosimetry","volume":"4","author":"Sharma","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"2026052207303453500_tqag052-B19","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.ejmp.2016.11.067","article-title":"Quantification in SPECT\/CT: calibration, methodology during Q. Metrix software implementation","volume":"32","author":"Michel","year":"2016","journal-title":"Phys Med"},{"key":"2026052207303453500_tqag052-B20","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3390\/diagnostics13020318","article-title":"Standardized uptake values on SPECT\/CT: a promising alternative tool for treatment evaluation and prognosis of metastatic neuroendocrine tumours","volume":"13","author":"Gherghe","year":"2023","journal-title":"Diagnostics"},{"key":"2026052207303453500_tqag052-B21","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/MNM.0000000000001792","article-title":"Estimation of absorbed dose to salivary glands in mCRPC patients undergoing 177Lu-PSMA-617 radioligand therapy using quantitative SPECT-CT at single time point: a single-center feasibility study","volume":"45","author":"Kaur","year":"2024","journal-title":"Nucl Med Commun"},{"key":"2026052207303453500_tqag052-B22","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.2967\/jnumed.111.100123","article-title":"Pamphlet no. 23: quantitative SPECT for patient specific 3-dimensional dosimetry in internal radionuclide therapy","volume":"53","author":"Dewaraja","year":"2012","journal-title":"J Nucl Med."},{"key":"2026052207303453500_tqag052-B23","first-page":"3","article-title":"Basic anatomical and physiological data for use in radiological protection: reference values. ICRP publication 89","volume":"32","author":"International Commission on Radiological Protection (ICRP)","year":"2002","journal-title":"Ann ICRP"},{"key":"2026052207303453500_tqag052-B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13550-020-00737-8","article-title":"Clinical implementation of PLANET\u00ae dose for dosimetric assessment after [177Lu] Lu-DOTA-TATE: comparison with dosimetry toolkit\u00ae and OLINDA\/EXM\u00ae V1.0. Santoro et al","volume":"11","author":"Santoro","year":"2021","journal-title":"EJNMMI Res"},{"key":"2026052207303453500_tqag052-B25","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.3390\/molecules27092617","article-title":"A review on the current state and future perspectives of [99mTc] Tc-housed PSMA-i in prostate cancer","volume":"27","author":"Brunello","year":"2022","journal-title":"Molecules"},{"key":"2026052207303453500_tqag052-B26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3390\/cancers14020273","article-title":"Quantitative analysis of SPECT-CT data in metastatic breast cancer patients\u2014the clinical significance","volume":"14","author":"Gherghe","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026052207303453500_tqag052-B27","doi-asserted-by":"publisher","first-page":"201","DOI":"10.4103\/ijnm.ijnm_77_23","article-title":"India\u2019s growing nuclear medicine infrastructure and emergence of radiotheranostics in cancer care: associated challenges and the opportunities to collaborate","volume":"38","author":"Singh","year":"2023","journal-title":"Indian J Nucl Med"},{"key":"2026052207303453500_tqag052-B28","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.2967\/jnumed.114.140426","article-title":"99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer","volume":"55","author":"Vallabhajosula","year":"2014","journal-title":"J Nucl Med"},{"key":"2026052207303453500_tqag052-B29","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2967\/jnumed.122.264296","article-title":"Eligibility for 177Lu-PSMA therapy depends on the choice of companion diagnostic tracer: a comparison of 68Ga-PSMA-11 and 99mTc MIP-1404 in metastatic castration-resistant prostate cancer","volume":"64","author":"Cook","year":"2023","journal-title":"J Nucl Med"},{"key":"2026052207303453500_tqag052-B30","doi-asserted-by":"publisher","first-page":"267","DOI":"10.4103\/1008-682X.192638","article-title":"Evaluation of 99mTc labeled PSMA-SPECT\/CT imaging in prostate cancer patients who have undergone biochemical relapse","volume":"19","author":"Su","year":"2017","journal-title":"Asian J Androl"},{"key":"2026052207303453500_tqag052-B31","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1007\/s00259-023-06176-6","article-title":"SPECT at the speed of PET: a feasibility study of CZT-based whole-body SPECT\/CT in the post 177Lu-DOTATATE and 177Lu-PSMA617 setting","volume":"50","author":"Song","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026052207303453500_tqag052-B32","doi-asserted-by":"publisher","first-page":"986","DOI":"10.2967\/jnumed.123.265603","article-title":"Theranostic radio pharmaceuticals: a universal challenging educational paradigm in nuclear medicine","volume":"64","author":"Urbain","year":"2023","journal-title":"J Nucl Med"},{"key":"2026052207303453500_tqag052-B33","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1038\/s41598-020-61129-5","article-title":"Evaluation of radiation dosimetry of 99mTc-HYNIC-PSMA and imaging in prostate cancer","volume":"10","author":"Zhang","year":"2020","journal-title":"Sci Rep"},{"key":"2026052207303453500_tqag052-B34","doi-asserted-by":"crossref","first-page":"7216","DOI":"10.3390\/molecules27217216","article-title":"99mTc-PSMA-T4\u2014novel SPECT tracer for metastatic PCa: from bench to clinic","volume":"27","author":"Maurin","year":"2022","journal-title":"Molecules"},{"key":"2026052207303453500_tqag052-B35","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/0146645314558019","article-title":"Radiation dose to patients from radiopharmaceuticals: a compendium of current information related to frequently used substances","volume":"44","author":"Mattsson","year":"2015","journal-title":"Ann ICRP"},{"key":"2026052207303453500_tqag052-B36","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1093\/rpd\/ncy111","article-title":"Estimation of the organ absorbed doses and effective dose from 68Ga-PSMA-11 PET scan","volume":"182","author":"Demirci","year":"2018","journal-title":"Radiat Prot Dosimetry"}],"container-title":["British Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjr\/advance-article-pdf\/doi\/10.1093\/bjr\/tqag052\/67318277\/tqag052.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/99\/1182\/1081\/67318277\/tqag052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/99\/1182\/1081\/67318277\/tqag052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T11:30:40Z","timestamp":1779449440000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjr\/article\/99\/1182\/1081\/8516583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":36,"journal-issue":{"issue":"1182","published-online":{"date-parts":[[2026,3,12]]},"published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/bjr\/tqag052","relation":{},"ISSN":["0007-1285","1748-880X"],"issn-type":[{"value":"0007-1285","type":"print"},{"value":"1748-880X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,3,12]]}}}